443 related articles for article (PubMed ID: 23899655)
1. Organotypic cultures as tools for optimizing central nervous system cell therapies.
Daviaud N; Garbayo E; Schiller PC; Perez-Pinzon M; Montero-Menei CN
Exp Neurol; 2013 Oct; 248():429-40. PubMed ID: 23899655
[TBL] [Abstract][Full Text] [Related]
2. Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson's disease.
Daviaud N; Garbayo E; Sindji L; Martínez-Serrano A; Schiller PC; Montero-Menei CN
Stem Cells Transl Med; 2015 Jun; 4(6):670-84. PubMed ID: 25925835
[TBL] [Abstract][Full Text] [Related]
3. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
[TBL] [Abstract][Full Text] [Related]
4. The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease.
Drouin-Ouellet J
Neurodegener Dis Manag; 2014; 4(4):297-307. PubMed ID: 25313986
[TBL] [Abstract][Full Text] [Related]
5. Biology and clinical application of neural stem cells.
Shimazaki T
Horm Res; 2003; 60 Suppl 3():1-9. PubMed ID: 14671388
[TBL] [Abstract][Full Text] [Related]
6. Graft and host interactions following transplantation of neural stem cells to organotypic striatal cultures.
Jäderstad LM; Jäderstad J; Herlenius E
Regen Med; 2010 Nov; 5(6):901-17. PubMed ID: 21082890
[TBL] [Abstract][Full Text] [Related]
7. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.
Somoza R; Juri C; Baes M; Wyneken U; Rubio FJ
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1530-40. PubMed ID: 20542127
[TBL] [Abstract][Full Text] [Related]
8. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Baker KA; Hong M; Sadi D; Mendez I
Exp Neurol; 2000 Apr; 162(2):350-60. PubMed ID: 10739641
[TBL] [Abstract][Full Text] [Related]
9. Stem cells for neurodegenerative disorders: where can we go from here?
Le Belle JE; Svendsen CN
BioDrugs; 2002; 16(6):389-401. PubMed ID: 12463763
[TBL] [Abstract][Full Text] [Related]
10. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.
Cui YF; Hargus G; Xu JC; Schmid JS; Shen YQ; Glatzel M; Schachner M; Bernreuther C
Brain; 2010 Jan; 133(Pt 1):189-204. PubMed ID: 19995872
[TBL] [Abstract][Full Text] [Related]
11. Adult cell therapy for brain neuronal damages and the role of tissue engineering.
Delcroix GJ; Schiller PC; Benoit JP; Montero-Menei CN
Biomaterials; 2010 Mar; 31(8):2105-20. PubMed ID: 20005569
[TBL] [Abstract][Full Text] [Related]
12. Translation of stem cell therapy for neurological diseases.
Schwarz SC; Schwarz J
Transl Res; 2010 Sep; 156(3):155-60. PubMed ID: 20801412
[TBL] [Abstract][Full Text] [Related]
13. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC
Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective properties of marrow-isolated adult multilineage-inducible cells in rat hippocampus following global cerebral ischemia are enhanced when complexed to biomimetic microcarriers.
Garbayo E; Raval AP; Curtis KM; Della-Morte D; Gomez LA; D'Ippolito G; Reiner T; Perez-Stable C; Howard GA; Perez-Pinzon MA; Montero-Menei CN; Schiller PC
J Neurochem; 2011 Dec; 119(5):972-88. PubMed ID: 21496021
[TBL] [Abstract][Full Text] [Related]
15. Neural Stem Cells and Human Induced Pluripotent Stem Cells to Model Rare CNS Diseases.
De Filippis L; Zalfa C; Ferrari D
CNS Neurol Disord Drug Targets; 2017; 16(8):915-926. PubMed ID: 28641519
[TBL] [Abstract][Full Text] [Related]
16. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease.
Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S
Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816
[TBL] [Abstract][Full Text] [Related]
17. The stem cells as a potential treatment for neurodegeneration.
Daniela F; Vescovi AL; Bottai D
Methods Mol Biol; 2007; 399():199-213. PubMed ID: 18309934
[TBL] [Abstract][Full Text] [Related]
18. Functional stem cell integration assessed by organotypic slice cultures.
Herlenius E; Thonabulsombat C; Forsberg D; Jäderstad J; Jäderstad LM; Björk L; Olivius P
Curr Protoc Stem Cell Biol; 2012 Nov; Chapter 2():Unit 2D.13. PubMed ID: 23154935
[TBL] [Abstract][Full Text] [Related]
19. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
[TBL] [Abstract][Full Text] [Related]
20. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.
Kolagar TA; Farzaneh M; Nikkar N; Khoshnam SE
Curr Stem Cell Res Ther; 2020; 15(2):102-110. PubMed ID: 31441732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
